Children’s Minnesota will pause prescribing puberty-blocking drugs and cross-sex hormones to patients under 18 starting February 27, a move explained as temporary but clearly driven by recent federal scrutiny and referrals for investigation into pediatric gender interventions.

Children’s Minnesota announced it will stop prescribing puberty-suppressing medications and cross-sex hormones to minors, effective February 27. The system framed the pause as temporary while federal pressure and investigations unfold. This is Minnesota’s only health system dedicated solely to pediatric care, and the decision signals a major shift in how such programs operate under federal scrutiny.

The pause follows a referral by HHS General Counsel Mike Stuart that pointed federal investigators at Children’s Minnesota and other hospitals for their roles in administering sex change drugs to children, Breitbart reported. That referral came after HHS launched a broader campaign targeting pediatric gender interventions. The hospital presented the action as compliance rather than a voluntary policy change.

On December 18, 2025, the Department of Health and Human Services unveiled proposed rules that would bar hospitals from providing sex change drugs and surgeries to minors as a condition of participating in Medicare and Medicaid. HHS Secretary Robert F. Kennedy, Jr. put the concern bluntly in public remarks and tied the proposed rule to enforcement mechanisms. The message was clear: federal participation rules can reach deep into hospital practices when taxpayer dollars are involved.

“Doctors across the country now provide needless and irreversible sex-rejecting procedures that violate their sacred Hippocratic oath, endangering the very lives that they are sworn to safeguard.”

Kennedy also called out the professional groups that championed pediatric gender interventions, saying they propagated a false promise about outcomes for young people. The Department emphasized the potential harms of these interventions, listing serious, irreversible risks. That list included infertility, impaired sexual function, diminished bone density, and altered brain development among the consequences cited by HHS.

“The American Medical Association, the American Academy of Pediatrics, peddled a lie that chemical and surgical sex-rejecting procedures could be good for children who suffer from gender dysphoria.”

In January, Stuart’s referral put Children’s Minnesota in the agency’s crosshairs and the hospital’s public statements shifted immediately to survival language. The Gender Health Program page acknowledged it had “Recently experienced an increase in federal actions directed at pediatric health systems like ours that provide this care.” The tone suggested the system was reacting to external pressure rather than reconsidering clinical judgment.

The hospital warned those federal actions could “Jeopardize the stability of Minnesota’s only comprehensive pediatric health care system, and they threaten our clinicians’ ability to practice medicine now and in the future.” That wording centers institutional risk, not the medical wisdom of prescribing irreversible hormonal treatments to adolescents. Hospitals are accountable to funders and regulators, and federal leverage often forces policy choices where ethics and science should lead.

Children’s Minnesota described the decision as “difficult” while maintaining that its gender care is “evidence-based and lifesaving for transgender and gender diverse youth.” At the same time, the system said it would continue mental health services and counseling within the Gender Health program. Prescriptions pause; counseling continues — a split that highlights how controversial the medical side of the program has become.

The federal push coincides with legal resistance from state governments. At least 19 states have filed suit against the administration over HHS’s move to restrict pediatric gender interventions, and Minnesota is among them. Those lawsuits frame the issue as access to care, but in many cases the litigation looks more like a political defense of prior policies than a fresh medical debate.

When hospitals inside the states suing the federal government begin stepping back from these treatments, it complicates the legal posture. The contrast between state litigation and provider behavior makes clear that this fight is as much about politics as medicine. Many European nations have already moved to restrict pediatric gender interventions after finding the evidence base weak.

Children’s Minnesota is one data point in a broader pattern: HHS has opened inquiries into multiple hospital systems for providing sex change drugs, and some investigations include surgical interventions. Stuart’s referral in January named several hospitals in addition to Children’s Minnesota, though not all have been publicly identified. The federal strategy aims to use funding conditions to change institutional incentives.

The proposed HHS rule links restrictions to Medicare and Medicaid participation, a lever few hospitals can ignore. When federal dollars are the lifeblood of a health system, compliance becomes a business decision as much as a medical one. Hospitals facing that choice will weigh ideology against solvency, and in many cases financial reality will win.

For families who believed medical professionals when they were told hormonal interventions were necessary, the pause raises painful questions. Some children are already on medications with lasting consequences, and that human cost preceded the federal action. The central question left hanging for clinicians and administrators is why it took a federal investigation to force a pause.